Skip to main content
Celemics, Inc. logo

Celemics, Inc. — Investor Relations & Filings

Ticker · 331920 ISIN · KR7331920009 KO Manufacturing
Open in API
Filings indexed 179 across all filing types
Latest filing 2025-03-04 AGM Information
Country KR South Korea
Listing KO 331920

About Celemics, Inc.

https://www.celemics.com/

Celemics, Inc. is a biotechnology company that develops and provides Next-Generation Sequencing (NGS) solutions for research and clinical applications. The company specializes in hybridization-based target enrichment technology, offering a comprehensive portfolio of products and services. This includes ready-to-use and customized NGS panels, whole exome sequencing kits, library preparation kits, modular accessories, and bioinformatics analysis services. Celemics' solutions support a wide range of fields, including oncology (somatic cancer, liquid biopsy), inherited diseases, pathogen analysis, pharmacogenomics, and immune repertoire profiling. A key focus is the development of end-to-end customized target enrichment panels, providing support from assay design and optimization to complete bioinformatics analysis. The company's proprietary technologies in probe design and molecular barcoding enable efficient analysis of diverse and challenging sample types.

Recent filings

Filing Released Lang Actions
주주총회집중일개최사유신고
AGM Information Classification · 1% confidence The document is a formal regulatory filing submitted by Celemix regarding the scheduling of their Annual General Meeting (AGM) on a 'concentrated date' (a date when many companies hold their AGMs). It explains the rationale for choosing this date and confirms the meeting details. Since it is a regulatory notification regarding meeting logistics rather than the meeting materials themselves or a proxy statement, it falls under the general regulatory filing category.
2025-03-04 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 1% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea used by companies to solicit shareholder votes for an upcoming Annual General Meeting (AGM). It contains details about the meeting, the agenda (such as approval of financial statements), and proxy solicitation information. While it includes financial data, it is explicitly labeled as a proxy solicitation document rather than an Annual Report or Financial Report. Therefore, it falls under the 'Proxy Solicitation & Information Statement' category.
2025-03-04 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 1% confidence The document is a regulatory filing from a Korean company (Celeomics) announcing a significant change (over 30%) in revenue or profit structure. It provides preliminary financial results (revenue, operating profit, net income) and explicitly states that these are provisional figures pending external audit. This type of disclosure is a standard regulatory requirement for listed companies to report material financial changes, fitting the 'Earnings Release' (ER) category as it provides key financial highlights before the full annual report is finalized. FY 2024
2025-02-19 Korean
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 1% confidence The document is a formal regulatory filing from the Korean stock market (DART system) announcing a 'Single Sale/Supply Contract' (단일판매ㆍ공급계약체결). It details the contract value, the counterparty (Korea Disease Control and Prevention Agency), and the contract duration. Since this is a specific announcement of a business contract and does not fit into the other specialized categories like M&A or financial reports, it is classified as a Regulatory Filing (RNS).
2024-12-17 Korean
분기보고서 (2024.09)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'Celemics' (주식회사 셀레믹스) covering the period from January 1, 2024, to September 30, 2024. It contains detailed financial information, business operations, and management disclosures, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2024
2024-11-14 Korean
단일판매ㆍ공급계약체결(자율공시)
Regulatory Filings Classification · 1% confidence The document is a regulatory filing from a Korean company (Celemix) announcing a 'Single Sales/Supply Contract' (단일판매ㆍ공급계약체결). It details the contract value, the counterparty (Korea Disease Control and Prevention Agency), and the contract period. Since this is a specific corporate announcement regarding a business contract that does not fit into categories like M&A, dividends, or financial reports, it falls under the general regulatory filing category.
2024-09-26 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.